AsepticSure™ Developments
Mon, 12/07/2009 - 21:52 — tina.burke
AsepticSure™ Developments
Posted by Medizone International, Inc. • November 30, 2009 • Printer-friendly
AsepticSureGlobe1
AsepticSure™
November 10, 2009
Early AsepticSure™ Third Round Trial Results
It is anticipated that AsepticSure™ will be extremely cost effective and adaptable to virtually any situation anywhere and have a global reach.
Third Round Trials are in progress at the Medizone International Research Laboratory located in Innovation Park at Queens University.
Early results have established that AsepticSure is able to reliably and predictably break through the 6 log barrier with MRSA.
This development is anticipated to significantly expand the utility for AsepticSure™, since by definition, any bacterial reduction beyond 6 logs (99.9999%) is considered STERILIZATION.
Second Round Trials Results from the second series of trials demonstrated a 5 log reduction (99.999%) in Pseudomonas Aeruginousa and a 4.4 log reduction (99.994%) in Methicillin Resistant Staph Aureus (MRSA).
AsepticSure™ Hospital Sterilization System
In parallel research conducted at BioZone Corporation, Medizone's engineering development partner, it was confirmed the AsepticSure™ hospital sterilization system can charge a room of 1,065 cubic feet to the target ozone level in less than 15 minutes, which is followed by the ozone decontamination phase. The same room can then be returned to a habitable standard (less than 0.02 ppm ozone) in 13 minutes using a separate ozone destruct technology. This confirms the start to finish time to complete the entire decontamination process can be achieved with minimal disturbance to normal hospital flow patterns.
Commercial Viability of AsepticSure™ Hospital Sterilization System
From a commercial viewpoint, the higher the "kill rate" in the shortest turn around time, the more favorably physicians and hospital administrators will view the system. Accordingly, Medizone now believes that the performance profile of its AsepticSure™ Sterilization System will exceed all the prerequisite requirements of affordability, practicability and unmatched efficacy, which will catapult it into the world market.
Tagged as: bioterrorism c difficile, bioterrorism countermeasure, bioterrorism mrsa, Biozone Corporation, BSL2A Certified Laboratory, c difficile, C Difficile Research, c difficile treatment, Claustricium difficile, hospital acquired infection, Hospital Sterilization, hospital treatement mrsa, hospital treatment c difficile, hospital treatment mrsa, Inc., Innovation Park, Medizone International, mrsa treatment, Ozone, Patented Hospital Sterilization, Queens University, Queens University Research
Article Date:
November 10, 2009
Posted by Medizone International, Inc. • November 30, 2009 • Printer-friendly
AsepticSureGlobe1
AsepticSure™
November 10, 2009
Early AsepticSure™ Third Round Trial Results
It is anticipated that AsepticSure™ will be extremely cost effective and adaptable to virtually any situation anywhere and have a global reach.
Third Round Trials are in progress at the Medizone International Research Laboratory located in Innovation Park at Queens University.
Early results have established that AsepticSure is able to reliably and predictably break through the 6 log barrier with MRSA.
This development is anticipated to significantly expand the utility for AsepticSure™, since by definition, any bacterial reduction beyond 6 logs (99.9999%) is considered STERILIZATION.
Second Round Trials Results from the second series of trials demonstrated a 5 log reduction (99.999%) in Pseudomonas Aeruginousa and a 4.4 log reduction (99.994%) in Methicillin Resistant Staph Aureus (MRSA).
AsepticSure™ Hospital Sterilization System
In parallel research conducted at BioZone Corporation, Medizone's engineering development partner, it was confirmed the AsepticSure™ hospital sterilization system can charge a room of 1,065 cubic feet to the target ozone level in less than 15 minutes, which is followed by the ozone decontamination phase. The same room can then be returned to a habitable standard (less than 0.02 ppm ozone) in 13 minutes using a separate ozone destruct technology. This confirms the start to finish time to complete the entire decontamination process can be achieved with minimal disturbance to normal hospital flow patterns.
Commercial Viability of AsepticSure™ Hospital Sterilization System
From a commercial viewpoint, the higher the "kill rate" in the shortest turn around time, the more favorably physicians and hospital administrators will view the system. Accordingly, Medizone now believes that the performance profile of its AsepticSure™ Sterilization System will exceed all the prerequisite requirements of affordability, practicability and unmatched efficacy, which will catapult it into the world market.
Tagged as: bioterrorism c difficile, bioterrorism countermeasure, bioterrorism mrsa, Biozone Corporation, BSL2A Certified Laboratory, c difficile, C Difficile Research, c difficile treatment, Claustricium difficile, hospital acquired infection, Hospital Sterilization, hospital treatement mrsa, hospital treatment c difficile, hospital treatment mrsa, Inc., Innovation Park, Medizone International, mrsa treatment, Ozone, Patented Hospital Sterilization, Queens University, Queens University Research
